← Back to Clinical Trials
Recruiting NCT06368544

NCT06368544 Effect of Early Gait Training on Knee Cartilage Degeneration After Anterior Cruciate Ligament Reconstruction

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06368544
Status Recruiting
Phase
Sponsor Peking University Third Hospital
Condition Anterior Cruciate Ligament Injuries
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-07-22
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 40 Years
Study Type INTERVENTIONAL
Interventions
lower-body positive-pressure

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-07-22 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A randomized controlled clinical study was conducted to elucidate the relationship between the lower extremity biomechanics of patients undergoing early gait training after ACLR surgery.The relationship between the biochemical characteristics of cartilage and the biomechanical risk index were proposed to providing exercise guidance and training for ACLR people and it is suggested that it can prevent and reduce the risk of cartilage degeneration early after operation.

Eligibility Criteria

Inclusion Criteria: 1. Patients with ACL rupture were diagnosed by MRI; 2. Unilateral ACL rupture for the first time should be performed in our hospital (Department of Sports Medicine, Peking University Third Hospital)The art of reconstruction; 3. Normal BMI range: 18.5-23.9 kg/m2; 4. Within 6 months from the trauma; 5. The affected knee joint has passed the acute stage, no obvious redness, pain,inflammation, and limited joint motion,basically restore joint motion. Exclusion Criteria: 1. BMI\<18.5 kg/m2 or BMI≥24 kg/m2); 2. There is a history of contralateral lower limb musculoskeletal system injury and surgery; 3. ACL injury time \> 6 months; 4. Outerbridge damage rating Ⅲ and Ⅳ; 5. Patients with meniscal tears who are expected to undergo meniscal suture surgery at the time of ACLR surgery; 6. Serious injury to the posterior cruciate ligament, medial collateral ligament, or lateral collateral ligament; 7. There is metabolic syndrome (obesity, dyslipidemia, diabetes, etc.), which will involve articular cartilage Epidemic diseases, serious cardiovascular and cerebrovascular diseases, etc.; 8. Those who do not want to accept this treatment

Contact & Investigator

Central Contact

ren shuang, doctor

✉ xixishuang123@126.com

📞 17610252992

Principal Investigator

ren shuang, doctor

STUDY CHAIR

Be affiliated with the organization

Frequently Asked Questions

Who can join the NCT06368544 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Anterior Cruciate Ligament Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06368544 currently recruiting?

Yes, NCT06368544 is actively recruiting participants. Contact the research team at xixishuang123@126.com for enrollment information.

Where is the NCT06368544 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT06368544 clinical trial?

NCT06368544 is sponsored by Peking University Third Hospital. The principal investigator is ren shuang, doctor at Be affiliated with the organization. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology